The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study
Matthew F. Daley(Kaiser Permanente), Eric Weintraub, Steven J. Jacobsen(Mayo Clinic), Christina L. Clarke(Kaiser Permanente), James G. Donahue(Brigham and Women's Hospital), Nicola P. Klein, Jonathan Duffy(Centers for Disease Control and Prevention), James D. Nordin(HealthPartners), Simon J. Hambidge, Michael L. Jackson(Kaiser Permanente Washington Health Research Institute), Stanley Xu(Kaiser Permanente), Jason M. Glanz(Kaiser Permanente), Grace Lee(Boston Children's Hospital), Allison L. Naleway(Centers for Disease Control and Prevention)
Cited by 19
Related Papers
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|720
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals: 2014 Update
|Infection Control and Hospital Epidemiology|2014|425
PD-1 up-regulation on CD4 <sup>+</sup> T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
|Science Translational Medicine|2018|364